Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
- PMID: 16136144
- DOI: 10.1038/nature03954
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Abstract
The recognition and elimination of tumours by T cells, a process termed cancer immunosurveillance, is effective against certain virus-associated cancers. Spontaneous tumours often induce a specific immune response and are therefore also immunogenic. However, it is not clear whether they can be controlled by T cells. The immunosurveillance hypothesis postulates that tumours, if they eventually grow, escaped T-cell recognition by losing immunogenicity. Here we show, by generating a mouse model of sporadic cancer based on rare spontaneous activation of a dormant oncogene, that immunogenic tumours do not escape their recognition but induce tolerance. In this model, tumours derive from single cells and express a tumour-specific transplantation rejection antigen. Whereas vaccinated mice remain tumour-free throughout their lifetime, naive mice always develop a progressively growing tumour. We also show that despite specific recognition by T cells, the tumours do not lose their intrinsic immunogenicity and are rejected after transplantation in T-cell-competent recipients. Furthermore, in the primary host tumour-induced tolerance is associated with the expansion of non-functional T cells. Together, our data argue against immunosurveillance of spontaneous cancer.
Comment in
-
Cancer immunology: cat and mouse games.Nature. 2005 Sep 1;437(7055):41-2. doi: 10.1038/437041a. Nature. 2005. PMID: 16136120 No abstract available.
Similar articles
-
The adaptive immune response to sporadic cancer.Immunol Rev. 2007 Dec;220:102-12. doi: 10.1111/j.1600-065X.2007.00578.x. Immunol Rev. 2007. PMID: 17979842 Review.
-
Adaptive immunity maintains occult cancer in an equilibrium state.Nature. 2007 Dec 6;450(7171):903-7. doi: 10.1038/nature06309. Epub 2007 Nov 18. Nature. 2007. PMID: 18026089
-
Cancer despite immunosurveillance: immunoselection and immunosubversion.Nat Rev Immunol. 2006 Oct;6(10):715-27. doi: 10.1038/nri1936. Epub 2006 Sep 15. Nat Rev Immunol. 2006. PMID: 16977338 Review.
-
Cancer immunology: cat and mouse games.Nature. 2005 Sep 1;437(7055):41-2. doi: 10.1038/437041a. Nature. 2005. PMID: 16136120 No abstract available.
-
Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.Scand J Immunol. 2007 Nov;66(5):546-54. doi: 10.1111/j.1365-3083.2007.02012.x. Scand J Immunol. 2007. PMID: 17953530
Cited by
-
Targeting cancer-specific mutations by T cell receptor gene therapy.Curr Opin Immunol. 2015 Apr;33:112-9. doi: 10.1016/j.coi.2015.02.005. Epub 2015 Feb 27. Curr Opin Immunol. 2015. PMID: 25728991 Free PMC article. Review.
-
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.J Exp Med. 2007 Apr 16;204(4):879-91. doi: 10.1084/jem.20061699. Epub 2007 Apr 2. J Exp Med. 2007. PMID: 17403934 Free PMC article.
-
Immunoediting is not a primary transformation event in a murine model of MLL-ENL AML.Life Sci Alliance. 2018 Jul 10;1(4):e201800079. doi: 10.26508/lsa.201800079. eCollection 2018 Aug. Life Sci Alliance. 2018. PMID: 30456365 Free PMC article.
-
T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine.Immunity. 2011 Jul 22;35(1):123-34. doi: 10.1016/j.immuni.2011.04.019. Epub 2011 Jul 14. Immunity. 2011. PMID: 21757379 Free PMC article.
-
Immunotherapy for prostate cancer: biology and therapeutic approaches.J Clin Oncol. 2011 Sep 20;29(27):3677-85. doi: 10.1200/JCO.2010.34.5025. Epub 2011 Aug 8. J Clin Oncol. 2011. PMID: 21825260 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases